Horizon Pharma Says Horizon-Labeled Vimovo Tablets Available In US - Quick Facts

(RTTNews) - Horizon Pharma Inc. (HZNP) announced Thursday that Horizon-labeled Vimovo (naproxen/esomeprazole magnesium) delayed-release tablets are now available to U.S. physicians.

Vimovo is approved for the relief of signs and symptoms of osteoarthritis or OA, rheumatoid arthritis or RA and ankylosing spondylitis and to decrease the risk of stomach (gastric) ulcers in patients at risk of developing stomach ulcers from treatment with NSAIDs.

Vimovo is a proprietary fixed-dose combination of enteric-coated naproxen, a pain-relieving non-steroidal anti-inflammatory drug or NSAID and immediate-release esomeprazole, a proton pump inhibitor or PPI.

The company said it expects to begin the commercial launch of Horizon-labeled VIMOVO with its primary care sales force on February 3, 2014.

According to the Arthritis Foundation, more than 50 million adults (one in every five) in the U.S. have doctor diagnosed arthritis. Arthritis prevalence increases with age with 50 percent of adults age 65 and older having some form of arthritis. By the year 2030, an estimated 67 million American adults will have arthritis.